Literature DB >> 18486110

Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model.

Chiho Hirata-Fukae1, Hui-Fang Li, Hyang-Sook Hoe, Audrey J Gray, S Sakura Minami, Katsuyoshi Hamada, Takako Niikura, Fang Hua, Hiroe Tsukagoshi-Nagai, Yuko Horikoshi-Sakuraba, Mohamed Mughal, G William Rebeck, Frank M LaFerla, Mark P Mattson, Nobuhisa Iwata, Takaomi C Saido, William L Klein, Karen E Duff, Paul S Aisen, Yasuji Matsuoka.   

Abstract

Epidemiological studies indicate that women have a higher risk of Alzheimer's disease (AD) even after adjustment for age. Though transgenic mouse models of AD develop AD-related amyloid beta (Abeta) and/or tau pathology, gender differences have not been well documented in these models. In this study, we found that female 3xTg-AD transgenic mice expressing mutant APP, presenilin-1 and tau have significantly more aggressive Abeta pathology. We also found an increase in beta-secretase activity and a reduction of neprilysin in female mice compared to males; this suggests that a combination of increased Abeta production and decreased Abeta degradation may contribute to higher risk of AD in females. In contrast to significantly more aggressive Abeta pathology in females, gender did not affect the levels of phosphorylated tau in 3xTg-AD mice. These results point to the involvement of Abeta pathways in the higher risk of AD in women. In addition to comparison of pathology between genders at 9, 16 and 23 months of age, we examined the progression of Abeta pathology at additional age points; i.e., brain Abeta load, intraneuronal oligomeric Abeta distribution and plaque load, in male 3xTg-AD mice at 3, 6, 9, 12, 16, 20 and 23 months of age. These findings confirm progressive Abeta pathology in 3xTg-AD transgenic mice, and provide guidance for their use in therapeutic research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18486110     DOI: 10.1016/j.brainres.2008.03.079

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  117 in total

Review 1.  Protective actions of sex steroid hormones in Alzheimer's disease.

Authors:  Christian J Pike; Jenna C Carroll; Emily R Rosario; Anna M Barron
Journal:  Front Neuroendocrinol       Date:  2009-05-07       Impact factor: 8.606

2.  Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer's disease.

Authors:  Kazuyuki Takata; Yoshihisa Kitamura; Yukinori Nakata; Yasuji Matsuoka; Hidekazu Tomimoto; Takashi Taniguchi; Shun Shimohama
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

3.  Autoimmune manifestations in the 3xTg-AD model of Alzheimer's disease.

Authors:  Monica Marchese; David Cowan; Elizabeth Head; Donglai Ma; Khalil Karimi; Vanessa Ashthorpe; Minesh Kapadia; Hui Zhao; Paulina Davis; Boris Sakic
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

4.  Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease.

Authors:  Maria I Fonseca; Rahasson R Ager; Shu-Hui Chu; Ozkan Yazan; Sam D Sanderson; Frank M LaFerla; Stephen M Taylor; Trent M Woodruff; Andrea J Tenner
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

5.  A selective role for ARMS/Kidins220 scaffold protein in spatial memory and trophic support of entorhinal and frontal cortical neurons.

Authors:  Aine M Duffy; Michael J Schaner; Synphen H Wu; Agnieszka Staniszewski; Asok Kumar; Juan Carlos Arévalo; Ottavio Arancio; Moses V Chao; Helen E Scharfman
Journal:  Exp Neurol       Date:  2011-03-16       Impact factor: 5.330

6.  Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy.

Authors:  Allan Wang; Pritam Das; Robert C Switzer; Todd E Golde; Joanna L Jankowsky
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

7.  Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.

Authors:  Jayasankar Kosaraju; R M Damian Holsinger; Lixia Guo; Kin Yip Tam
Journal:  Mol Neurobiol       Date:  2016-10-03       Impact factor: 5.590

8.  Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease.

Authors:  Tatiana Melnikova; DaMin Park; Lauren Becker; Deidre Lee; Eugenia Cho; Nuzhat Sayyida; Jing Tian; Karen Bandeen-Roche; David R Borchelt; Alena V Savonenko
Journal:  Neurobiol Dis       Date:  2016-08-26       Impact factor: 5.996

9.  Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.

Authors:  Qiu-Lan Ma; Fusheng Yang; Emily R Rosario; Oliver J Ubeda; Walter Beech; Dana J Gant; Ping Ping Chen; Beverly Hudspeth; Cory Chen; Yongle Zhao; Harry V Vinters; Sally A Frautschy; Greg M Cole
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

10.  In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the beta-amyloid depositing mice.

Authors:  Jose Morales-Corraliza; Matthew J Mazzella; Jason D Berger; Nicole S Diaz; Jennifer H K Choi; Efrat Levy; Yasuji Matsuoka; Emmanuel Planel; Paul M Mathews
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.